Schizophrenia-Psychotic Disorders & Antipsychotics

 (Haga un click en la información del journal para acceder al resúmen)

5 – doble-ciego o metanálisis; 4 – subanálisis o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión

 

3 - Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia

Kim, Sung-Wan; Shin, Il-Seon; Kim, Jae-Min; Lee, Jeong-Hoon; Lee, Yo-Han; Yang, Su-Jin; Yoon, Jin-Sang

Clinical Neuropharmacology: September/October 2009 - Volume 32 - Issue 5 - pp 243-249

 

3 - Association of Adverse Drug Effects With Subjective Well-Being in Patients With Schizophrenia Receiving Stable Doses of Risperidone

Kim, Jong-Hoon; Kim, Min-Jung

Clinical Neuropharmacology: September/October 2009 - Volume 32 - Issue 5 - pp 250-253

 

3 - The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial

David L. Penn, Richard S.E. Keefe, Sonia M. Davis, Piper S. Meyer, Diana O. Perkins, Diane Losardo and Jeffrey A. Lieberman

Schizophrenia Research. Volume 115, Issue 1, November 2009, Pages 17-23

 

5 - Reduction of functional disability with atypical antipsychotic treatment: A randomized long term comparison of ziprasidone and haloperidol

Philip D. Harvey, Elizabeth Pappadopulos, Ilise Lombardo and Charlotte M. Kremer

Schizophrenia Research. Volume 115, Issue 1, November 2009, Pages 24-29

 

3! - Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour

Greg C. Smith, Mark H. Vickers, Emmanuelle Cognard and Peter R. Shepherd

Schizophrenia Research. Volume 115, Issue 1, November 2009, Pages 30-40

 

3 - Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand

Yang Guo, Hai Zhang, Xuetao Chen, Wenxian Cai, Jianjun Cheng, Yushe Yang, Guozhang Jin and Xuechu Zhen

Schizophrenia Research. Volume 115, Issue 1, November 2009, Pages 41-49

 

3!! -The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: A naturalistic study of the North American Prodrome Longitudinal Sample

Elaine F. Walker, Barbara A. Cornblatt, Jean Addington, Kristin S. Cadenhead, Tyrone D. Cannon, Thomas H. McGlashan, Diana O. Perkins, Larry J. Seidman, Ming T. Tsuang, Scott W. Woods and Robert Heinssen

Schizophrenia Research. Volume 115, Issue 1, November 2009, Pages 50-57

 

3 - Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remission

Julio Bobes, Antonio Ciudad, Enric Álvarez, Luis San, Pepa Polavieja and Inmaculada Gilaberte

Schizophrenia Research. Volume 115, Issue 1, November 2009, Pages 58-66

 

3! - Association of Pre-Onset Cannabis, Alcohol, and Tobacco Use With Age at Onset of Prodrome and Age at Onset of Psychosis in First-Episode Patients

Michael T. Compton, Mary E. Kelley, Claire E. Ramsay, Makenya Pringle, Sandra M. Goulding, Michelle L. Esterberg, Tarianna Stewart, and Elaine F. Walker

Am J Psychiatry Published October 1, 2009

 

3 - Intervention in Individuals at Ultra-High Risk for Psychosis: A Review and Future Directions

Patrick D. McGorry, Barnaby Nelson, G. Paul Amminger, Andreas Bechdolf, Shona M. Francey, Gregor Berger, Anita Riecher-Rössler, Joachim Klosterkötter, Stephan Ruhrmann, Frauke Schultze-Lutter, Merete Nordentoft, Ian Hickie, Philip McGuire, Michael Berk, Eric Y. H. Chen, Matcheri S. Keshavan, and Alison R. Yung

J Clin Psychiatry 2009;70(9):1206–1212

 

GRATIS 3 - From drugs to deprivation: a Bayesian framework for understanding models of psychosis

P. R. Corlett, C. D. Frith and P. C. Fletcher

Psychopharmacology. Volume 206, Number 4 / November, 2009: 515-530

 

3 - Role of cannabis and endocannabinoids in the genesis of schizophrenia

Emilio Fernandez-Espejo, Maria-Paz Viveros, Luis Núñez, Bart A. Ellenbroek and Fernando Rodriguez de Fonseca

Psychopharmacology. Volume 206, Number 4 / November, 2009: 531-549Review

 

GRATIS 3 - Asenapine effects in animal models of psychosis and cognitive function

Hugh M. Marston, Jared W. Young, Frederic D. C. Martin, Kevin A. Serpa, Christopher L. Moore, Erik H. F. Wong, Lisa Gold, Leonard T. Meltzer, Marc R. Azar, Mark A. Geyer and Mohammed Shahid

Psychopharmacology. Volume 206, Number 4 / November, 2009: 699-714

 

3 - Lurasidone: a new drug in development for schizophrenia

Jonathan M Meyer ‌, Antony D Loebel ‌ & Edward Schweizer ‌

Expert Opinion on Investigational Drugs. Posted online on 28 Sep 2009

 

3! - Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings

S. Navari and P. Dazzan

Psychological Medicine (2009), 39:1763-1777 (2009), 39:1763-1777

 

3 - Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study

Robert C. Smith, Jean-Pierre Lindenmayer, John M. Davis, Erin Kelly, Thomas F. Viviano, James Cornwell, Qiaoyan Hu, Anzalee Khan, and Sumathi Vaidhyanathaswamy

J Clin Psychiatry. Online ahead of print: October 6, 2009

 

3 - Early Development of Childhood-Onset Schizophrenia

C. Eggers, D. Bunk

Fortschr Neurol Psychiatr 2009; 77: 558-567

3! - If cannabis caused schizophrenia—how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations

Matt Hickman, Peter Vickerman, John Macleod, Glyn Lewis, Stan Zammit, James Kirkbride & Peter Jones

Addiction. Volume 104 Issue 11, Pages 1856 - 1861

 

5 - A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia

Joris Berwaerts, Adriaan Cleton, Stefaan Rossenu, Krishna Talluri, Bart Remmerie, Luc Janssens, Sandra Boom, Michelle Kramer, and Mariëlle Eerdekens

Journal of Psychopharmacology. First published on October 13, 2009

 

3 - Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study

Jesús De la Gándara, Luis San Molina, Gabriel Rubio, Alexander Rodriguez-Morales, Rebeca Hidalgo Borrajo and José Antonio Burón

Expert Review of Neurotherapeutics. October 2009, Vol. 9, No. 10, Pages 1463-1474

 

3! - Schizophrenia in the Offspring of Antenatally Depressed Mothers in the Northern Finland 1966 Birth Cohort: Relationship to Family History of Psychosis

Pirjo Mäki, Tiina Riekki, Jouko Miettunen, Matti Isohanni, Peter B. Jones, Graham K. Murray, and Juha Veijola

Am J Psychiatry Published October 15, 2009

 

3! - Schizophrenia Susceptibility Genes Directly Implicated in the Life Cycles of Pathogens: Cytomegalovirus, Influenza, Herpes simplex, Rubella, and Toxoplasma gondii

C.J. Carter

Schizophrenia Bulletin 2009 35(6):1163-1182

 

3 - In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation

Manoranjenni Chetty, Fabrizio d'Esposito, Wei V. Zhang, John Glen, Glenys Dore, Zvijezdana Stankovic, Robert J. Edwards, Iqbal Ramzan & Michael Murray

British Journal of Clinical Pharmacology. Volume 68 Issue 4, Pages 574 - 579

 

3 - Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparisons Between Subgroups of Participants of the European First Episode Schizophrenia Trial (EUFEST)

Han Boter, Eske M. Derks, W. Wolfgang Fleischhacker, M. Davidson, and René S. Kahn, for the EUFEST Study Group

J Clin Psychiatry. October 20, 2009

 

3 - Exposure-Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation
Sunny Chapel, Matt M. Hutmacher, George Haig, Howard Bockbrader, Rik de Greef, Sheldon H. Preskorn, and Richard L. Lalonde

J Clin Pharmacol 2009 49: 1297 -1308

 

3 - Single- and Multiple-Dose Pharmacokinetics and Dose Proportionality of the Psychotropic Agent Paliperidone Extended Release
Sandra Boom, Krishna Talluri, Luc Janssens, Bart Remmerie, Marc De Meulder, Stefaan Rossenu, Nancy van Osselaer, Marielle Eerdekens, and Adriaan Cleton

J Clin Pharmacol 2009 49: 1318 -1330

 

3 - Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

Steven M. Grauer, Virginia L. Pulito, Rachel L. Navarra, Michele P. Kelly, Cody Kelley, Radka Graf, Barbara Langen, Sheree Logue, Julie Brennan, Lixin Jiang, Erik Charych, Ute Egerland, Feng Liu, Karen L. Marquis, Michael Malamas, Thorsten Hage, Thomas A. Comery, and Nicholas J. Brandon

JPET 331:574-590, 2009

 

3 - Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

S Volpi, C Heaton, K Mack, J B Hamilton, R Lannan, C D Wolfgang, L Licamele, M H Polymeropoulos and C Lavedan

Molecular Psychiatry (2009) 14, 1024–1031

 

3! - Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

L. Citrome

International Journal of Clinical Practice. Published Online: 14 Oct 2009

 

3! - Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies

C. J. Bushe, A. J. Bradley, S. Doshi, J. Karagianis

International Journal of Clinical Practice. Published Online: 19 Oct 2009

 

3 - Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors

Shona L. Kirk, John Glazebrook, Ben Grayson, Joanna C. Neill and Gavin P. Reynolds

Psychopharmacology. Volume 207, Number 1 / November, 2009: 119-125

 

3 - Exposure-Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation
Sunny Chapel, Matt M. Hutmacher, George Haig, Howard Bockbrader, Rik de Greef, Sheldon H. Preskorn, and Richard L. Lalonde

J Clin Pharmacol 2009 49: 1297 -1308

 

3 - In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation

Manoranjenni Chetty, Fabrizio d'Esposito, Wei V. Zhang, John Glen, Glenys Dore, Zvijezdana Stankovic, Robert J. Edwards, Iqbal Ramzan & Michael Murray

British Journal of Clinical Pharmacology. Volume 68 Issue 4, Pages 574 - 579

 

3 - Association study of serotonergic gene variants with antipsychotic-induced adverse reactions

Al-Janabi, Ismail; Arranz, Maria J.; Blakemore, Alexandra I.F.; Saiz, Pilar A.; Susce, Margaret T.; Glaser, Paul E.A.; Clark, Daniel; de Leon, Jose

Psychiatric Genetics: December 2009 - Volume 19 - Issue 6 - pp 305-311

 

3 - Effects of the Antipsychotic Risperidone on Dopamine Synthesis in Human Brain Measured by Positron Emission Tomography with L-[β-¹¹C]DOPA: A Stabilizing Effect for Dopaminergic Neurotransmission?

Hiroshi Ito, Harumasa Takano, Hidehiko Takahashi, Ryosuke Arakawa, Michie Miyoshi, Fumitoshi Kodaka, Masaki Okumura, Tatsui Otsuka, and Tetsuya Suhara

The Journal of Neuroscience, October 28, 2009, 29(43):13730-13734

 

3 - The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: Relationship with treatment response

Aygun Ertugrul, Bilge Volkan-Salanci, Koray Basar, Kader Karli Oguz, Basaran Demir, Eser Lay Ergun, Senem Senturk, Belkis Erbas, Aysenur Cila and Berna Ulug

Psychiatry Research: Neuroimaging. Volume 174, Issue 2, 30 November 2009, Pages 121-129

 

3 - Pharmacokinetic and Pharmacodynamic Interactions Between Carbamazepine and Aripiprazole in Patients With Schizophrenia

Nakamura, Akifumi; Mihara, Kazuo; Nagai, Goyo; Suzuki, Takeshi; Kondo, Tsuyoshi

Therapeutic Drug Monitoring: October 2009 - Volume 31 - Issue 5 - pp 575-578

 

GRATIS 3 - Asenapine

Herbert Y. Meltzer, Argyris Dritselis, Uma Yasothan & Peter Kirkpatrick

Nature Reviews Drug Discovery 8, 843-844 (November 2009)

 

GRATIS 3 - Effects of adding depot antipsychotic medication to oral antipsychotic regimen on treatment compliance in schizophrenic patients

SS Eker, C Akkaya, Ş Cangür, A Sarandöl, G Deniz, S Kırlı

Klinik Psikofarmakoloji Bülteni Volume 19, Number 3, 2009

 

GRATIS 3 - The effectiveness of risperidone long-acting injection in oral antipsychotic non-adherent patients with schizophrenia: A retrospective study

C Akkaya, A Sarandol, VO Kotan, Ş Cangür, A Aydın, S Kırlı

Klinik Psikofarmakoloji Bülteni Volume 19, Number 3, 2009

 

GRATIS 4 - Ziprasidone in Black Patients with Schizophrenia: Analysis of Four Short-term, Double-blind Studies

William B. Lawson, Barry K. Herman, Antony Loebel, Irina Lazariciu, and Mansoor Malik

CNS Spectr. 2009;14(9):478-486

 

GRATIS 3 - Partial Adherence to Antipsychotic Medication Impacts the Course of Illness in Patients With Schizophrenia: A Review

Prakash S. Masand, Miquel Roca, Martin S. Turner, and John M. Kane

Prim Care Companion J Clin Psychiatry. 2009; 11(4): 147–154

 

Regresar a RESÚMENES OCTUBRE 2009